Reg­u­la­to­ry in­tel­li­gence: Up­date on re­gen­er­a­tive med­i­cine ad­vanced ther­a­pies des­ig­na­tions

This ar­ti­cle dis­cuss­es the scope and pur­pose of the spe­cial des­ig­na­tion for Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­pies (RMAT) cre­at­ed by the pas­sage of the 21st Cen­tu­ry Cures Act. The au­thors ex­plain the ben­e­fits ex­pect­ed to be re­al­ized with RMAT, such as keep­ing the US glob­al­ly com­pet­i­tive in the field. They pro­vide a tal­ly of prod­ucts re­ceiv­ing the spe­cial des­ig­na­tion to date and a cur­rent count, by year, of prod­ucts for which RMAT des­ig­na­tion has been re­quest­ed.

In­tro­duc­tion

Sec­tion 3033 of the 21st Cen­tu­ry Cures Act, ti­tled “Ac­cel­er­at­ed Ap­proval for Re­gen­er­a­tive Ad­vanced Ther­a­pies,” cre­at­ed a spe­cial des­ig­na­tion for Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­pies (RMAT). A prod­uct is el­i­gi­ble for RMAT des­ig­na­tion if it is a re­gen­er­a­tive med­i­cine ther­a­py, such as cell ther­a­py, ther­a­peu­tic tis­sue en­gi­neer­ing prod­uct, hu­man cell and tis­sue prod­uct, gene ther­a­py or any com­bi­na­tion prod­uct us­ing such ther­a­pies or prod­ucts, and is in­tend­ed to treat, mod­i­fy, re­verse or cure a se­ri­ous or life-threat­en­ing dis­ease or con­di­tion and pre­lim­i­nary clin­i­cal ev­i­dence in­di­cates that the drug has the po­ten­tial to ad­dress un­met med­ical needs for such dis­ease or con­di­tion.

Oth­er na­tion­al bod­ies have in re­cent years made spe­cial reg­u­la­to­ry pro­vi­sions to rec­og­nize the val­ue of re­gen­er­a­tive med­i­cine prod­ucts. For ex­am­ple, Japan’s SAKI­GAKE des­ig­na­tion,  was in­tro­duced in 2015 to pro­mote R&D of re­gen­er­a­tive med­i­cines and oth­er in­no­vate phar­ma­ceu­ti­cals and med­ical de­vices.

RMAT des­ig­na­tion has helped keep the US com­pet­i­tive in the glob­al field, while ad­dress­ing spe­cif­ic needs and re­quire­ments of re­gen­er­a­tive med­i­cine ad­vanced ther­a­py prod­ucts. The ben­e­fits of an RMAT des­ig­na­tion are the same as the ben­e­fits for break­through ther­a­pies and in­clude in­ter­ac­tions with FDA to ex­pe­dite de­vel­op­ment and re­view of the prod­uct and con­sid­er­a­tion of the prod­uct for pri­or­i­ty re­view or ac­cel­er­at­ed ap­proval. Re­ceiv­ing RMAT des­ig­na­tion al­so al­lows for in­creased flex­i­bil­i­ty in clin­i­cal tri­al de­sign, for in­stance, in the num­ber of clin­i­cal tri­al sites. De­vel­op­ers al­so have the po­ten­tial to use pa­tient reg­istry da­ta and oth­er re­al-world sources in post-ap­proval path­ways.

While de­vel­op­ers seek­ing break­through des­ig­na­tion are re­quired to show that their ther­a­peu­tic can­di­date would pro­vide a sub­stan­tial im­prove­ment over ex­ist­ing ther­a­pies, RMAT des­ig­na­tion on­ly re­quires that the ther­a­py have the po­ten­tial to ad­dress un­met med­ical need.

With RMAT des­ig­na­tions avail­able for more than two years, what have we seen so far?

Table 1 pro­vides FDA’s lat­est tal­ly of RMAT des­ig­na­tions by year. On­ly 2018 rep­re­sents a full year. For 2019, the num­ber of re­quests is at a high­er rate (19 re­quests through 10 April 2019) but the num­ber grant­ed is about the same rate as for 2018 (about 1.5 re­quests grant­ed per month).

Table 1. Met­rics on RMAT Re­quests by Year1
Fis­cal Year To­tal Re­quests
Re­ceived
Grant­ed De­nied With­drawn
2017 31 11 18 2
2018 47 18 27 2
2019 19 4 8 1

So far, no RMAT-des­ig­nat­ed prod­ucts have re­ceived mar­ket­ing ap­proval and no RMAT des­ig­na­tions have been re­port­ed with­drawn or re­scind­ed.

Fig­ure 1 pro­vides met­rics on des­ig­na­tion re­quests by ther­a­peu­tic area as of Sep­tem­ber 2018. The largest cat­e­go­ry is neu­rol­o­gy, fol­lowed by on­col­o­gy. This is sur­pris­ing be­cause sci­en­tif­ic pub­li­ca­tions of re­gen­er­a­tive med­i­cines for on­col­o­gy far out­pace those for neu­rol­o­gy.2

Fig­ure 2 pro­vides met­rics on des­ig­na­tion re­quests by prod­uct type as of March 2019. The great­est num­ber of des­ig­na­tion re­quests have been for cell ther­a­py prod­ucts with al­lo­gene­ic prod­ucts out­pac­ing au­tol­o­gous prod­ucts.

Fig­ure 1. RMAT Des­ig­na­tion Re­quests by Ther­a­peu­tic Area3

Fig­ure 2. RMAT des­ig­na­tion re­quests by prod­uct type4


Table 2 pro­vides a list­ing of the pub­licly an­nounced RMAT des­ig­na­tions. Twen­ty-eight have been an­nounced so far. There have been 33 RMAT des­ig­na­tions grant­ed as of 1 April 2019,3 thus five are cur­rent­ly unan­nounced.

Table 2. List­ing of Pub­licly An­nounced RMAT Des­ig­na­tions
Prod­uct Name Spon­sor Date Award­ed De­scrip­tion
HU­MA­CYL  Hu­ma­cyte 20 March 2017 acel­lu­lar ves­sel for vas­cu­lar ac­cess in he­modial­y­sis pa­tients
RVT-802  En­zy­vant 17 April 2017 al­lo­gene­ic thymic tis­sue for Di­ge­orge Syn­drome
jCell  jCyte 2 May 2017 hu­man reti­nal prog­en­i­tor cells for re­tini­tis pig­men­tosa
Ixmy­lo­cel-T  Veri­cel 10 May 2017 au­tol­o­gous ex­pand­ed mul­ti­cel­lu­lar ther­a­py for heart fail­ure due to is­chemic di­lat­ed car­diomy­opa­thy
Strat­a­Graft Mallinck­rodt 18 Ju­ly 2017 tis­sue en­gi­neered full thick­ness re­gen­er­a­tive skin tis­sue for deep par­tial thick­ness burns
ATIR101  Kiadis 20 Sep­tem­ber 2017 cell ther­a­py for leukemia
Lenti­Glo­bin  Blue­bird 1 Oc­to­ber 2017 gene ther­a­py for sick­le cell dis­ease
AST-OP­CI  As­te­r­ias 2 Oc­to­ber 2017 cell ther­a­py for spinal cord in­jury
Mul­ti­Stem  Ather­sys 5 Oc­to­ber 2017 cell ther­a­py is­chemic stroke
JCAR017  Juno (Cel­gene) 1 No­vem­ber 2017 car-t ther­a­py for re­lapsed or re­frac­to­ry dif­fuse large b-cell lym­phoma
CE­VA101  Cel­l­va­tion (Fortress Biotech) 8 No­vem­ber 2017 cell ther­a­py for trau­mat­ic brain in­jury
MPC-150-IM 
Revas­cor
Mesoblast 21 De­cem­ber 2017 mes­enchy­mal pre­cur­sor cell ther­a­py for heart fail­ure
EB-101  Abeona 29 Jan­u­ary 2018 gene ther­a­py for re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa
CAP-1002  Capri­cor 5 Feb­ru­ary 2018 cell ther­a­py for duchenne mus­cu­lar dy­s­tro­phy
Am­nioFix  MiMedx 9 March 2018 tis­sue en­gi­neered al­lo­gene­ic mi­cronized de­hy­drat­ed hu­man am­nion/chori­on mem­brane for os­teoarthri­tis of the knee
ABO-102  Abeona 23 April 2018 gene ther­a­py for San­fil­ip­po Syn­drome type a
VM202 Vi­roMed May 2018 gene ther­a­py for painful di­a­bet­ic pe­riph­er­al neu­ropa­thy
NSR-REP1  Night­star Ther­a­peu­tics 14 June 2018 gene ther­a­py for choroi­dere­ma
CLBS14-NOR­DA  Cal­adrius Bio­sciences 19 June 2018 No-Op­tion Re­frac­to­ry Dis­abling Angi­na (NOR­DA)
VY-AADC  Voy­ager 21 June 2018 gene ther­a­py for Parkin­son’s dis­ease
Romye­lo­cel-L  Celler­ant 2 Ju­ly 2018 cell ther­a­py for pre­ven­tion of in­fec­tions dur­ing neu­trope­nia
AT132 Au­dentes Ther­a­peu­tics 21 Au­gust 2018 gene ther­a­py for X-linked my­otubu­lar my­opa­thy
Avance Ax­o­Gen 29 Oc­to­ber 2018 tis­sue en­gi­neered nerve graft for pe­riph­er­al nerve re­pair
P-BC­MA-101 Po­sei­da Ther­a­peu­tics No­vem­ber 5, 2018 gene mod­i­fied CAR-T cell ther­a­py for re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma
Li­fileu­cel Io­vance Bio­ther­a­peu­tics 6 No­vem­ber 2018 adop­tive gene-mod­i­fied cell ther­a­py for metasta­t­ic melanoma
RP-L102 Rock­et Phar­ma­ceu­ti­cals 27 No­vem­ber 2018 lentivi­ral vec­tor-based gene ther­a­py for Fan­coni ane­mia
FCR001 Ta­laris Ther­a­peu­tics (Re­generex) 18 April 2019 al­lo­gene­ic cell ther­a­py for im­mune tol­er­ance in kid­ney trans­plant
ECT-001 Ex­CellThera 23 April 2019 mul­ti­ple myelo­ma, high-risk leukemia, and oth­er hema­to­log­ic ma­lig­nan­cies

In the fol­low­ing month, the Al­liance for Re­gen­er­a­tive Med­i­cine plans to launch a data­base uti­liz­ing pub­licly avail­able and com­pa­ny-pro­vid­ed in­for­ma­tion to cre­ate a pub­lic list of RMAT re­cip­i­ents, as well as oth­er ex­pe­dit­ed ap­proval des­ig­na­tions award­ed in the Unit­ed States, Eu­rope, and Japan.

Clear­ly, the RMAT des­ig­na­tion pro­gram has been very ac­tive for FDA and pop­u­lar for spon­sors. We look for­ward to see­ing the first prod­ucts ap­proved un­der this pro­gram.

Ref­er­ences

  1. Cu­mu­la­tive CBER Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py (RMAT) Des­ig­na­tion Re­quests Re­ceived by Fis­cal Year. FDA web­site. https://www.fda.gov/vac­cines-blood-bi­o­log­ics/cel­lu­lar-gene-ther­a­py-prod­ucts/cu­mu­la­tive-cber-re­gen­er­a­tive-med­i­cine-ad­vanced-ther­a­py-rmat-des­ig­na­tion-re­quests-re­ceived-fis­cal. Ac­cessed 6 May 2019.
  2. Based on PubMed search com­par­ing “re­gen­er­a­tive med­i­cine on­col­o­gy” to “re­gen­er­a­tive med­i­cine neu­rol­o­gy” or “cell gene ther­a­py neu­rol­o­gy” to “cell gene ther­a­py on­col­o­gy,” 3 May 2019.
  3. Bryan WW. “Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py (RMAT) Des­ig­na­tion.” Amer­i­can So­ci­ety of Gene and Cell Ther­a­py. Li­ai­son Meet­ing. 13 Sep­tem­ber 2018.
  4. From Wil­son Bryan pre­sen­ta­tion to the Al­liance for Re­gen­er­a­tive Med­i­cine Li­ai­son Meet­ing on 28 March 2019.

Janet Lynch Lam­bert joined the Al­liance for Re­gen­er­a­tive Med­i­cine (ARM) in 2017 as the or­ga­ni­za­tion’s first CEO. She most re­cent­ly served as the act­ing head of en­gage­ment for the All of Us Re­search Pro­gram at the Na­tion­al In­sti­tutes of Health and as head of the Out­reach Of­fice in the Of­fice of the NIH Di­rec­tor. Pri­or to join­ing NIH, she was vice pres­i­dent of gov­ern­ment re­la­tions and head of the Wash­ing­ton of­fice of Life Tech­nolo­gies.

William Si­et­se­ma is vice pres­i­dent, glob­al reg­u­la­to­ry af­fairs at Cal­adrius Bio­sciences, a com­pa­ny that fo­cus­es on in­no­v­a­tive cell ther­a­pies for dif­fi­cult-to-treat dis­eases. Pri­or to Cal­adrius, he was glob­al reg­u­la­to­ry lead at Am­gen and vice pres­i­dent, glob­al reg­u­la­to­ry con­sult­ing and sub­mis­sions at Kendle In­ter­na­tion­al/INC Re­search and ad­junct pro­fes­sor of phar­ma­ceu­ti­cal sci­ences at the Uni­ver­si­ty of Cincin­nati, Col­lege of Phar­ma­cy. He may be con­tact­ed at william@si­et­se­ma.com.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

Weeks away from the results of ongoing US and China trials testing its experimental antiviral remdesivir, Gilead is going to trial the failed Ebola drug in a small group of coronavirus patients in England and Scotland. The United Kingdom is also home to a range of other therapeutic efforts, as the pandemic rages on across the globe.

On Tuesday, Southampton, UK-based startup Synairgen kicked off a mid-stage placebo-controlled study testing its experimental drug, SNG001 — an inhaled formulation of interferon-beta-1a — that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials.

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­sciences se­cures $70M Se­ries A

Just before Christmastime, Howard Federoff got a tip from Washington: There was a new virus in China. And this one could be bad.

News report of the virus had not yet appeared. Federoff, a neuroscientist, was briefed because years before, he was vetted as part of a group — he didn’t give a name for the group — to consult for the US government on emerging scientific issues. His day job, though, was CEO of Aspen Neurosciences, a Parkinson’s cell therapy startup that days before had come out of stealth mode and gave word to investors they were hoping to raise $70 million. That, Federoff realized, would be difficult if a pandemic shut down the global economy.

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

Despite worries about regulatory delays due to new work arrangements under Covid-19, the FDA appears intent to go full speed ahead with its everyday work, not only granting priority review to a stem cell therapy for acute graft versus host disease but also plotting an advisory committee meeting for it.

With a PDUFA date of September 30, the journey of the drug — remestemcel-L, or Ryoncil — could shed light on the agency’s capacity to facilitate drug development unrelated to Covid-19.

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

President Trump has a new favorite Covid-19 drug.

After a conversation with Japanese Prime Minister Shinzo Abe, Politico reports, the president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally Rudy Giuliani has been talking up unproven cell therapy efforts on Twitter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.